Related Experiment Video
Updated: Jun 28, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Treatment of visceral leishmaniasis: a review of current treatment practices
1Groupe de Recherche en Immunopathologie de la Leishmaniose, Faculté de Médecine, Université de Nice-Sophia-Antipolis et Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Nice, Hôpital de l'Archet, Nice, France. marty@unice.fr
Abstract:
Visceral leishmaniasis (VL) is a systemic protozoan infection that infects a million people living in subtropical and tropical areas. Once established, the clinical course of untreated disease leads to death. Recent, large-scale epidemics in east Africa and India and the emergence of a new epidemic in patients infected with HIV makes VL a priority for the World Health Organization. Pentavalent antimonials have been the mainstay of the treatment for > 60years. The progressive appearance of antimonial resistance, the developments of lipid formulations of amphotericin B and a new oral administered drug (miltefosine) have changed the pattern of VL treatment. The prohibitive cost of new therapies leads to different treatment practices according to the socioeconomic and cultural status of each region.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Leishmaniasis
American Trypanosomiasis
Anthelminthic Agents
Antiprotozoal Agents

